Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs.com. The U.S. Food and Drug Administration (FDA) first approved it in 2014 ...

Cardiologists have spent decades trying to stabilize the fatty plaques that clog arteries, but a new wave of immunotherapy is ...

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and ...

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Dozens of drugs can alter the immune system and affect activity of immune checkpoint inhib ...

Scientists have designed an immunotherapy that reduces plaque in the arteries of mice, presenting a possible new treatment strategy against heart disease. The antibody-based therapy could complement ...

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the ...

SCAC, while rare, is primarily driven by the human papillomavirus (HPV) and accounts for about 85% of all anal cancers. There ...

Long-term clinical trials show patients with stage four kidney cancer are living a decade or more beyond previous ...

Two new studies highlight the potential of fecal microbiota transplantation as a boon to cancer immunotherapy.

Fecal microbiota transplants (FMT) can dramatically improve cancer treatment, suggest two groundbreaking studies published in ...

Engineered BiTE molecule draws T cells to eliminate FAP+ modulated smooth muscle cells, reducing plaque burden across mouse atherosclerosis models.